SecBot SecBot
8-K ·Filed Nov 5, 2026

AKBA

Akebia Therapeutics, Inc.
BEARISH
Impact 5/10
Horizonimmediate Processed11d 20h ago SEC0001517022-26-000083
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The sharp decline in Auryxia revenue from generic erosion is now the dominant headwind, and Vafseo revenue is not yet growing fast enough to offset it. Watch for the TDAPA expiration impact on Vafseo access in 2027 and for any update on refinancing the senior secured term loan facility.

DirectionBearish
Confidencehigh
Horizonimmediate

Drugs in focus

AKBA drug pipeline →

Auryxia

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially available since September 2014.
Next catalyst
None dated

What to watchAuryxia has no upcoming binary catalyst; its revenue trajectory is a steady decline driven by Teva's generic entry in March 2026. The next meaningful event for Akebia as a whole is the January 2027 expiration of Vafseo's TDAPA transitional add-on payment, which could pressure Vafseo pricing. Investors should watch Q4 2026 Auryxia revenue (expected in early March 2027) to gauge the pace of generic erosion.

Price Chart

Loading chart...

Executive Summary

Akebia reported Q3 2026 total revenue of $36.9M, down 37% YoY from $58.8M, driven by a 53% decline in Auryxia revenue to $20.0M due to generic competition. Vafseo revenue was essentially flat at $14.8M, and the company posted a net loss of $14.4M vs net income of $0.5M a year ago. The revenue miss versus the $46.9M consensus and the swing to a loss are the key negatives, partially offset by positive VOICE trial data and a stable cash position of $159.3M.

Key Financial Metrics

EPS
−$0.05
Revenue
$36.9M
est $46.9M · -21.3% · -37.2% YoY

Key Facts

  • Total revenue $36.9M, down 37% YoY from $58.8M, missing the $46.9M consensus
  • Vafseo net product revenue $14.8M, essentially flat YoY ($14.3M) and down from Q2 2026 due to customer inventory reduction
  • Auryxia net product revenue $20.0M, down 53% YoY from $42.5M due to generic competition and pricing pressure
  • Net loss of $14.4M vs net income of $0.5M in Q3 2025; included a $1.3M restructuring charge
  • Cash and cash equivalents $159.3M at quarter end, down from $184.8M at Dec 31, 2025
  • Positive VOICE trial data presented at ASN Kidney Week showed statistically significant improved safety outcomes for vadadustat vs ESA
  • VOCAL topline data met primary endpoint of non-inferiority to ESA in maintaining hemoglobin
  • Approximately 11,500 patients on Vafseo at end of Q3, up 140% YoY and 8.1% sequentially
  • First patient dosed in Phase 2 basket trial of ebribafusp alfa; initial data expected in 2027

Financial Impact

Total revenue of $36.9M missed consensus of $46.9M by 21%; net loss of $14.4M vs prior year net income of $0.5M; GAAP EPS of $(0.05) missed consensus of $(0.03)

revenueepsnet income

Segment Breakdown

SegmentRevenueGrowth
Vafseo$14.8M+3.5%
Auryxia$20.0M-52.9%

Risk Factors

  • Auryxia revenue continues to decline faster than Vafseo can grow, pressuring total revenue
  • Vafseo revenue impacted by customer inventory reduction and TDAPA expiration approaching
  • Net loss widened to $14.4M and operating cash burn continues; cash burn rate needs monitoring
  • Plan to refinance senior secured term loan facility adds execution risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001517022-26-000083
Document: akba-20261105.htm0001517022-26-000083
Document: 0001517022-26-000083-index-headers.html0001517022-26-000083
Document: 0001517022-26-000083-index.html0001517022-26-000083
Document: 0001517022-26-000083.txt0001517022-26-000083
8-K Data (Synthetic)0001517022-26-000083

Track record

11 reports on AKBA

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +14.04% at T+5 after the Jun 30, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry $0.4700 Now $0.4490 −4.47% settles Nov 17
  2. Nov 16, 2026today Press Release Neutral 3/10 Entry $0.4775 Now $0.4490 −5.97% settles Nov 17
  3. Nov 5, 202611d ago 8-K Bearish 5/10 Viewing No price data
  4. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $0.4255 to $0.4013 Now $0.4490 −5.52% ▲ +5.69% +6.00% vs SPY
  5. Oct 26, 202621d ago Press Release Bullish 6/10 Entry $0.6438 to $0.6604 Now $0.4490 −30.26% ▲ +2.58% +2.02% vs SPY
  6. Oct 23, 202624d ago 8-K Bearish 7/10 Entry $0.6438 to $0.6604 Now $0.4490 +30.26% ▼ −2.58% −2.02% vs SPY
  7. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.7020 to $0.6955 Now $0.4490 −36.04% ▼ −0.93% −1.21% vs SPY
  8. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9800 to $0.9326 Now $0.4490 −54.18% ▼ −4.84% −4.12% vs SPY
  9. Jun 30, 202619w ago 8-K Bullish 7/10 Entry $1.14 to $1.21 Now $0.4490 −60.61% ▲ +6.14% +6.28% vs SPY
  10. Apr 30, 202628w ago Press Release Neutral 1/10 Entry $1.40 Now $0.4490 −67.93% No price data
Showing 10 of 11

US Market Status

Market Closed · Opens in 5h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026